Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO) (ALC-DRD2-APO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00437177|
Recruitment Status : Unknown
Verified April 2009 by Hospital Universitari Vall d'Hebron Research Institute.
Recruitment status was: Recruiting
First Posted : February 19, 2007
Last Update Posted : April 29, 2009
|Condition or disease||Intervention/treatment||Phase|
|Alcoholism||Drug: apomorphine Drug: [(123)I] iodobenzamide||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence: Predictive Value for Relapse|
|Study Start Date :||January 2007|
|Estimated Primary Completion Date :||December 2009|
|Estimated Study Completion Date :||June 2010|
- Drug: apomorphine
Apomorphine 0.05 mg/kg subcutaneously at hospital admission and at discharge. Abstinent participants at 3 months will receive a third dose.
- Drug: [(123)I] iodobenzamide
[(123)I] iodobenzamide 185 MBq I.V., at discharge.
- To detertmine the agreement rate of the dopaminergic sensibility assessed by two different techiniques: the apomorphine test and and IBZM SPECT. [ Time Frame: 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00437177
|Psychiatry Service, Hospital Universitari Vall d'Hebron||Recruiting|
|Barcelona, Catalonia, Spain, 08036|
|Contact: Miquel Casas, Prof firstname.lastname@example.org|
|Contact: Xavier Castells email@example.com|
|Principal Investigator: Miquel Casas, Prof|
|Principal Investigator:||Miquel Casas, Prof||Psychiatry Service, Hospital Universitari Vall d'Hebron|